CASE SERIES OF BURKHOLDERIA PSEUDOMALLEI CAUSING MELIOIDOSIS (PULMONARY, CEREBRAL, AND SPLENIC ABSCESS)

Authors

  • Prasanna S Department of Microbiology, Shri Sathya Sai Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed to be University), Chengalpattu, Tamil Nadu, India.
  • Mayuri Mahajan Department of Microbiology and Pathology, Dr. Hedgewar Hospital and Research Centre, Akola, Maharashtra, India.
  • Nikhil Mahajan Department of Pediatrics and Neonatology, Dr. Hedgewar Hospital and Research Centre, Akola, Maharashtra, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i5.47043

Keywords:

Burkholderia pseudomallei, Melioidosis, Respiratory, Cerebral, Splenic abscess

Abstract

Burkholderia pseudomallei is soil saprophytic Gram-negative bacilli that cause a fatal disease called melioidosis. Melioidosis is capable of causing cutaneous infection and systemic infections in the respiratory tract, cardiovascular, gastrointestinal, urinary, skin and soft tissue, and musculoskeletal and central nervous systems. Here, we report rare forms of pulmonary, cerebral, and splenic abscess case series of melioidosis caused by B. pseudomallei. Imported cases have been reported among tourists, immigrants, and soldiers who returned from endemic areas. The acquisition of infection is through percutaneous, inhalation, and ingestion of contaminated water; person-to-person transmission is very rare. Melioidosis cases are primarily found in the rainfall season and are usually associated with risk factors such as diabetes, alcoholism, and chronic renal diseases. However, 20–26% of cases were not associated with predisposing conditions. The identification is based on colony morphology, Gram stain, antibiotic susceptibility testing, and other supportive automated and molecular assays when we suspect B. pseudomallei. There are two phases, the intensive and eradication phases, in managing melioidosis. In the intensive phase, ceftazidime for 2 weeks showed efficacy in almost 50% of cases, and the eradication phase treatment with co-trimoxazole and doxycycline or amoxicillin/clavulanic acid for 3–6 months showed an excellent response. The improper clinical diagnosis and management of B. pseudomallei can lead to complications. Hence, early diagnosis with microbiological approaches such as culture, biochemical reactions, or automated systems available and antimicrobial sensitivity testing will cure the patient quickly without mortality.

Downloads

Download data is not yet available.

Author Biographies

Mayuri Mahajan, Department of Microbiology and Pathology, Dr. Hedgewar Hospital and Research Centre, Akola, Maharashtra, India.

Department of Microbiology and Pathology

Nikhil Mahajan, Department of Pediatrics and Neonatology, Dr. Hedgewar Hospital and Research Centre, Akola, Maharashtra, India.

Paediatrics, Dr Hedgewar Hospital and Research Centre, Akola

References

Currie BJ. Burkholderia pseudomallei, Burkhloderia mallei: Melioidosis and glanders. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s Principle and Practice of Infectious Disease. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010. p. 2869-77.

Vernon M. Pseudomonadaceae. In: Minor LE, Vernon M, editors. Bacteriologiemédicale. 2nd ed. Paris: Flammarion; 1989. p. 555-98.

Anuradha K, Meena AK, Lakshmi V. Isolation of Burkholderia pseudomallei from a case of septicaemia: A case report. Indian J Med Microbiol 2003;21:129-32. doi: 10.1016/S0255-0857(21)03138-8, PMID 17642999

Jesudason MV, Anbarasu A, John TJ. Septicaemic melioidosis in a tertiary care hospital in south India. Indian J Med Res 2003;117:119- 21. PMID 14575177

Viswaroop BS, Balaji V, Mathai E, Kekre NS. Melioidosis presenting as genitourinary infection in two men with diabetes. J Postgrad Med 2007;53:108-10. doi: 10.4103/0022-3859.32210, PMID 17495376

Kosuwon W, Taimglang T, Sirichativapee W, Jeeravipoolvarn P. Melioidotic septic arthritis and its risk factors. J Bone Joint Surg Am 2003;85:1058-61. doi: 10.2106/00004623-200306000-00011, PMID 12784002

Wiersinga WJ, Virk HS, Torres AG, Currie BJ, Peacock SJ, Dance DA, et al. Melioidosis. Nat Rev Dis Primers 2018;4:17107. doi: 10.1038/ nrdp.2017.107, PMID 29388572

Dance DA. Melioidosis as an emerging global problem. Acta Trop 2000;74:115-9. doi: 10.1016/s0001-706x(99)00059-5, PMID 10674638

Vuddhakul V, Tharavichitkul P, Na-Ngam N, Jitsurong S, Kunthawa B, Noimay P, et al. Epidemiology of Burkholderia pseudomallei in Thailand. Am J Trop Med Hyg 1999;60:458-61. doi: 10.4269/ ajtmh.1999.60.458, PMID 10466977

Inglis TJ, Garrow SC, Henderson M, Clair A, Sampson J, O’Reilly L, et al. Burkholderia pseudomallei traced to water treatment plant in Australia. Emerg Infect Dis 2000;6:56-9. doi: 10.3201/eid0601.000110, PMID 10653571

Currie BJ, Jacups SP. Intensity of rainfall and severity of melidosis, Australia. Emerg Infect Dis 2003;9:1538-42. doi: 10.3201/ eid0912.020750, PMID 14720392

Cheng AC, Currie BJ. Melidosis: Epidemiology, pathology, and management. Clin Microbiol Rev 2005;18:383-416. doi: 10.1128/ CMR.18.2.383-416.2005, PMID 15831829

Dhodapkar R, Sujatha S, Sivasangeetha K, Prasanth G, Parija SC. Burkholderia pseudomallei infection in a patient with diabetes presenting with multiple splenic abscesses and abscess in the foot: A case report. Cases J 2008;1:224. doi: 10.1186/1757-1626-1-224, PMID 18840270

Dancet DA. Melioidosis: The tip of the iceberg? Clin Microbiol Rev 1991;4:52-60.

Ashdown LR. In-vitro activities of the newer β-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei. Antimicrob Agents Chemother 1988;32:1435-6. doi: 10.1128/AAC.32.9.1435, PMID 3196005

White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989;2:697-701. doi: 10.1016/s0140- 6736(89)90768-x, PMID 2570956

Chetchotisakd P, Chierakul W, Chaowagul W, Anunnatsiri S, Phimda K, Mootsikapun P, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): A multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014;383:807-14. doi: 10.1016/S0140-6736(13)61951-0, PMID 24284287

Inglis TJ. The treatment of melioidosis. Pharmaceuticals (Basel) 2010;3:1296-303. doi: 10.3390/ph3051296, PMID 27713302

Published

07-05-2023

How to Cite

S, P., M. Mahajan, and N. Mahajan. “CASE SERIES OF BURKHOLDERIA PSEUDOMALLEI CAUSING MELIOIDOSIS (PULMONARY, CEREBRAL, AND SPLENIC ABSCESS)”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 5, May 2023, pp. 4-6, doi:10.22159/ajpcr.2023.v16i5.47043.

Issue

Section

Case Study(s)